You are here

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19104 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Has been identified for coronary artery bypass grafting (CABG), aortic and/or mitral
valve replacement, or combined CABG and cardiac valve replacement procedures that
require cardiopulmonary bypass (CPB).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Requires an emergent or "emergency" CABG and/or cardiac valve replacement.

NCT00838383
Pfizer
Completed
Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now